Identification of ANC-3 as a Novel Therapeutic Candidate for Anaplastic Thyroid Cancer Through Drug Screening and Multi-Platform Validation
Open Access
- 9 June 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5222
Abstract
Anaplastic thyroid carcinoma (ATC) is a rare but highly aggressive malignancy characterized by rapid progression, early metastasis, and extremely poor survival outcomes. Effective therapeutic options remain limited, highlighting the need for efficient and biologically relevant preclinical drug-discovery platforms. In this study, high-throughput compound screening using human ATC cell lines identified ANC-3 as a potential anticancer candidate. Its antitumor activity was evaluated through cytotoxicity and functional assays, zebrafish xenograft validation with live fluorescence imaging, colony-formation assays, and bulk RNA sequencing with pathway enrichment analyses. ANC-3 demonstrated consistent antitumor effects by significantly inhibiting cell viability, migration, invasion, and clonogenic survival, while also suppressing tumor growth in zebrafish xenograft models. Transcriptomic analyses revealed modulation of multiple oncogenic pathways, including MAPK, Ras, and NF-κB signaling. Collectively, these findings support zebrafish xenograft-based screening as a rapid and scalable platform for ATC drug discovery and suggest ANC-3 as a promising multi-pathway inhibitor warranting further preclinical development.Keywords
Funding Information
- Korea University Ansan Hospital (O2414021)
This publication has 27 references indexed in Scilit:
- ENDOCAN TUTHYREF network consensus recommendations: Anaplastic thyroid cancerAnnales d'Endocrinologie, 2025
- Anaplastic thyroid cancer:Improved understanding of what remains a deadly diseaseThe Surgeon, 2023
- Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer TherapyJournal of Medicinal Chemistry, 2022
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket studyAnnals of Oncology, 2022
- Immunotherapy in Anaplastic Thyroid Cancer: Much Yet to Be LearnedAACE Clinical Case Reports, 2021
- Infusion of imaging and therapeutic molecules into the plant virus-based carrier cowpea mosaic virus: Cargo-loading and deliveryJournal of Controlled Release, 2013
- Synthesis of Novel Amide Derivatives with In Vitro Antiproliferative and Cytotoxic ActivityHeteroatom Chemistry, 2012
- Patient-derived tumour xenografts as models for oncology drug developmentNature Reviews Clinical Oncology, 2012
- Hypoxia-induced metastasis model in embryonic zebrafishNature Protocols, 2010
- Transparent Adult Zebrafish as a Tool for In Vivo Transplantation AnalysisCell Stem Cell, 2008